These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36820052)

  • 1. Longitudinal study of Alzheimer's disease biomarkers, allostatic load, and cognition among memory clinic patients.
    Adedeji DO; Holleman J; Juster RP; Udeh-Momoh CT; Kåreholt I; Hagman G; Aspö M; Adagunodo S; Håkansson K; Kivipelto M; Solomon A; Sindi S
    Brain Behav Immun Health; 2023 Mar; 28():100592. PubMed ID: 36820052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex differences in Alzheimer's disease: plasma MMP-9 and markers of disease severity.
    Tsiknia AA; Sundermann EE; Reas ET; Edland SD; Brewer JB; Galasko D; Banks SJ;
    Alzheimers Res Ther; 2022 Nov; 14(1):160. PubMed ID: 36324151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.
    Nho K; Kueider-Paisley A; Ahmad S; MahmoudianDehkordi S; Arnold M; Risacher SL; Louie G; Blach C; Baillie R; Han X; Kastenmüller G; Trojanowski JQ; Shaw LM; Weiner MW; Doraiswamy PM; van Duijn C; Saykin AJ; Kaddurah-Daouk R;
    JAMA Netw Open; 2019 Jul; 2(7):e197978. PubMed ID: 31365104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cortisol, cognition and Alzheimer's disease biomarkers among memory clinic patients.
    Holleman J; Adagunodo S; Kåreholt I; Hagman G; Aspö M; Udeh-Momoh CT; Solomon A; Kivipelto M; Sindi S
    BMJ Neurol Open; 2022; 4(2):e000344. PubMed ID: 36277478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
    Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
    J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease.
    Mouton-Liger F; Dumurgier J; Cognat E; Hourregue C; Zetterberg H; Vanderstichele H; Vanmechelen E; Bouaziz-Amar E; Blennow K; Hugon J; Paquet C
    Alzheimers Res Ther; 2020 Jul; 12(1):88. PubMed ID: 32690068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
    Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
    Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The structural MRI markers and cognitive decline in prodromal Alzheimer's disease: a 2-year longitudinal study.
    Wei H; Kong M; Zhang C; Guan L; Ba M;
    Quant Imaging Med Surg; 2018 Nov; 8(10):1004-1019. PubMed ID: 30598878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression.
    Jahn T; Clark C; Kerksiek A; Lewczuk P; Lütjohann D; Popp J
    J Steroid Biochem Mol Biol; 2021 Jan; 205():105785. PubMed ID: 33171206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Associations of Cerebrospinal Fluid ApoE and Biomarkers of Alzheimer's Disease: Exploring Interactions With Sex.
    Liu Y; Song JH; Xu W; Hou XH; Li JQ; Yu JT; Tan L; Chi S;
    Front Neurosci; 2021; 15():633576. PubMed ID: 33746700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive Dispersion Is Not Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Results from the European Prevention of Alzheimer's Dementia (EPAD) v500.0 Cohort.
    Watermeyer T; Marroig A; Ritchie CW; Ritchie K; Blennow K; Muniz-Terrera G;
    J Alzheimers Dis; 2020; 78(1):185-194. PubMed ID: 32955462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.
    Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ
    Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression.
    Tsiknia AA; Edland SD; Sundermann EE; Reas ET; Brewer JB; Galasko D; Banks SJ;
    Mol Psychiatry; 2022 Oct; 27(10):4314-4322. PubMed ID: 35768637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
    Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
    BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.